Ravulizumab shortage status
No active shortage currently reported by the regulators Mederti tracks.
Last updated 9 Jul 2026 · sourced from official medicines regulators
- Generic name (INN)
- Ravulizumab
- Brand names
- Ultomiris
- Class
- Auto-created by Agenzia Italiana del Farmaco — Carenze scraper
Recent shortage history
- Italy: resolved 10 Jul 2022 (began 10 Jul 2022)
Frequently asked questions
Is Ravulizumab currently in shortage?
No active shortage of Ravulizumab is currently reported by any of the national medicines regulators Mederti tracks. Shortages can emerge quickly — this page updates daily from official sources.
Where does this Ravulizumab shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Get alerted when Ravulizumab status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.